Can Glypican3 be Diagnostic for Early Hepatocellular Carcinoma among Egyptian Patients? |
Abdelgawad, Iman Attia
(Department of Clinical and Chemical Pathology, NCI, Cairo University)
Mossallam, Ghada Ibrahim (Department of Clinical and Chemical Pathology, NCI, Cairo University) Radwan, Noha Hassan (Department of Clinical and Chemical Pathology, NCI, Cairo University) Elzawahry, Heba Mohammed (Department of Medical Oncology, NCI, Cairo University) Elhifnawy, Niveen Mostafa (Department of Clinical and Chemical Pathology, NCI, Cairo University) |
1 | Gomaa A, Hendy O, Aboraia G, et al (2012). The diagnostic Value of Peripheral blood Glypican-3 in patients with hepatocellular carcinoma. World J Med Sci, 7, 105-12. |
2 | Hippo Y, Watanabe K, Watanabe A, et al (2004). Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma. Cancer Res, 64, 2418-23. DOI ScienceOn |
3 | Iglesias V, Centeno G, Pascucceli H, et al (2008). Expression pattern of glypican-3 (GPC-3) during human embryonic and fetal development. Histol Histopathol, 23, 1333-40. |
4 | Inoue K, Sugiyama H, Ogawa H, et al (1994). WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood, 84, 3071-9. |
5 | Jackbovic B, Jothy S (2007). Glypican-3 from the mutations of Simpson-Golabi-Behmel genetic syndrome to a tumor marker for hepatocellular carcinoma. Exp Mol Pathol, 82, 184-9. DOI ScienceOn |
6 | Kandil D, Cooper K (2009). Glypican-3: A novel diagnostic marker for hepatocellular carcinoma and more. Adv Anat Pathol, 16, 125-9. DOI ScienceOn |
7 | Lehman EM, Wilson ML (2009). Epidemiology of hepatitis viruses among hepatocellular carcinoma cases and healthy people in Egypt: a systemic review and meta-analysis. Int J Cancer, 124, 690-7 DOI ScienceOn |
8 | Li BD, Zhao QC, Zhu YT, et al (2006). Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells. Zhonghua Wai Ke Za Zhi, 44, 458-62. |
9 | Liu H, Li P, Zhai Y, et al (2010). Diagnostic value of Glypican-3 in serum and liver for primary hepatocellular carcinoma. World J Gastroenterol, 16, 4410-5. DOI |
10 | Trerotoli P, Fransvea E, Angelotti U et al (2009).Tissue expression of squamous cellular carcinoma antigen (SCCA) is inversely correlated to tumor size in HCC. Molecular Cancer, 8, 29. DOI ScienceOn |
11 | Yan D, He Q, Chen Y, et al (2011). Detection of -fetoprotein and glypican-3 mRNAs in the peripheral blood of hepatocellular carcinoma patients by using multiple FQ-RT-PCR. J Clin Lab Anal, 25, 113-7. DOI ScienceOn |
12 | Yasuda E, Kumada T, Toyoda H, et al (2010). Evaluation for clinical utility of GPC-3, measured by a commericially available ELISA kit with GPC-3 antibody, as a serological and histological marker for HCC. Hepatol Res, 40, 477-85. DOI ScienceOn |
13 | Youssef M, El-Sharkawy S, Abbas N, et al (2010). Clinical utility of Glypican-3 in hepatocellular carcinoma. Int J Integr Biol, 10, 41-7. |
14 | Zakhary N, Khodeer S, Ezzat H, et al (2012). Impact of PIVKAII in diagnosis of hepatocellular carcinoma. International Conference on Ecological Environmental and Biology Sciences, ICEEBS, Jan. 7-8 Dubai. |
15 | National Cancer Institute Cairo (2010). Cancer registry 2002-2007. Website: www.nci.edu.eg.data. |
16 | Anwar WA, Khaled HM, Amra HA, et al (2008). Changing pattern of hepatocellular carcinoma (HCC) and its risk factors in Egypt: possibilities for prevention. Mutat Res, 659, 176-84. DOI ScienceOn |
17 | El-Shenawy S, El Sabawi M, Sheble N, et al (2012). Diagnotic Role of serum Glypican-3 as a tumor marker for hepatocellular carcinoma. Nature Sci, 10, 32-8. |
18 | Filmus J, Capurro M (2004). Glypican-3 and alphafetoprotein as diagnostic tests for hepatocellular carcinoma. Mol Diag, 8, 207-12. DOI |
19 | Nakatsura T, Nishimura Y (2005). Usefulness of the novel oncofetal antigen, Glypican 3, for diagnosis of hepatocellular carcinoma and melanoma. Bio Drugs, 19, 71-7. |
20 | Nakatsura T, Yoshitake Y, Senju S, et al (2003). Glypican 3 : Overexpressed specially in human hepatocellular carcinoma., is a novel tumor marker. Biochem Biophys Res Commun, 306, 16-25. DOI ScienceOn |
21 | Nishimura Y, Nakatsura T, Senju S (2008). Usefulness of a novel oncofetal antigen, Glypican 3, for diagnosis and immunotherapy of hepatocellular carcinoma. Nihon Rinsho Meneki Gakkai Kaishi, 31, 383-91. DOI ScienceOn |
22 | Qiao SS, Cui Z, Gong L, et al (2011). Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma. Hepato-Gastroenterol, 58, 1718-24. |
23 | Shafizadeh N, Ferrel P, Karkar S (2008). Utility and limitation of Glypican-3 expression for the of hepatocellular carcinoma at both ends of the differentiation spectrum. Mod Pathol, 21, 1011-8. DOI ScienceOn |
24 | Sung YK, Hwang SY, Park MK et al (2003). Glypican-3 is overexpressed in human hepatocellular carcinoma. Cancer Sci, 94, 259-62. DOI ScienceOn |
25 | Suriawinata A, Thung SN (2010). Molecular signature of early hepatocellular carcinoma. Oncol, 78, 36-9. DOI ScienceOn |
26 | Tangkijvanich P, Chanmer T, Komtong S, et al (2010). Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers. J Gastroenterol Hepatol, 25, 129-37. DOI ScienceOn |